Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 1
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
BRCA1/2 mutation
breast cancer · Therapy Not Normalized
BRCA1/2 mutation is flagged as manual review required because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03499353 | https://clinicaltrials.gov/study/NCT03206203 | https://clinicaltrials.gov/study/NCT02365805 | https://clinicaltrials.gov/study/NCT02681562 | https://clinicaltrials.gov/study/NCT00256217 | https://clinicaltrials.gov/study/NCT01898117 | https://clinicaltrials.gov/study/NCT07484776